FDA approves Enhertu as neoadjuvant, adjuvant treatment for breast cancer

The U.S. Food and Drug Administration has approved AstraZeneca's Enhertu (fam-trastuzumab deruxtecan-nxki) for both the neoadjuvant and adjuvant treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.